Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 10, 2025
Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
BioCentury | Nov 19, 2024
Product Development
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
BioCentury | Nov 19, 2024
Deals
More bispecific deals in China: Aclaris/Biosion, Ouro/Keymed, Avenzo/VelaVigo
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
BioCentury | Jul 8, 2024
Deals
Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class
Small molecule program, now in Phase II, could challenge injectable blockbuster; joins IBD drug Omvoh in pharma’s immunology arsenal
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Feb 24, 2024
Data Byte
EMA’s CHMP backs Biogen’s ALS drug and an IgAN therapy from CSL, Travere
The agency’s February decisions also include positive opinions for Tizveni, Voydeya and Zynyz, and label expansions for six therapies
BioCentury | Nov 27, 2023
Product Development
Nov. 27 Quick Takes: BioNTech grows U.K. presence
Plus: FDA approval for SpringWorks, setback for Aldeyra and updates from Sanofi, Regeneron, GSK, Abeona, Roivant, Sosei Heptares, Xenon, Arvinas, Teva
BioCentury | Nov 16, 2023
Discovery & Translation
Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 14, 2023
Finance
Nov. 13 Quick Takes: Legend finds next CAR partner in Novartis
Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry
Items per page:
1 - 10 of 506